Palo Alto Investors LP Revance Therapeutics, Inc. Call Options Transaction History
Palo Alto Investors LP
- $790 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
202Shares Held
81.8MCall Options Held
490KPut Options Held
147K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.26MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$15.4 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X03.57MShares$9.17 Million0.06% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...